²²⁵Ac-FPI-2059 (²²⁵Ac-3BP-227, ²²⁵Ac-IPN-01087) is the ²²⁵Ac-labeled analogue of ¹⁷⁷Lu-IPN-1087, a neurotensin antagonist peptide targeting NTSR-1 (NTSR1). The ¹⁷⁷Lu-labeled drug was developed for the treatment of ductal pancreatic adenocarcinoma (DPAC) and potentially other oncology indications, and these will probably be the same set of indications for the ²²⁵Ac-analogue.
In June 2022, FDA has cleared the IND applications for ²²⁵Ac-FPI-2059 and the corresponding imaging analogue ¹¹¹In-FPI-2058.

Target/Mechanism: NTSR1

Carrier/Ligand: 3BP-227

Radiation Type: alpha particle (α)